

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2526)

(1) PROPOSED ADJUSTMENT OF BUSINESS SCOPE; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the **“Company”**) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**).

PROPOSED ADJUSTMENT OF BUSINESS SCOPE

In light of the business and operation needs of the Company, the board (the **“Board”**) of directors (the **“Directors”**) of the Company proposes to adjust the business scope of the Company (the **“Proposed Adjustment of Business Scope”**). The details of the Proposed Adjustment of Business Scope will be set out in the proposed amendments to the articles of association of the Company (the **“Articles of Association”**) below. The Proposed Adjustment of Business Scope is subject to the satisfaction of the following conditions:

- (i) a special resolution being passed by the shareholders of the Company (the **“Shareholders”**) at the extraordinary general meeting of the Company (the **“EGM”**) to approve the Proposed Adjustment of Business Scope and the proposed amendments to the Articles of Association; and
- (ii) the registration of changes to the market supervision and administration authorities in respect of the Proposed Adjustment of Business Scope.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In light of the Proposed Adjustment of Business Scope, the Board proposes to make the following amendments to the Articles of Association to reflect the changes in the business scope:

Original Articles of Association	Amended Articles of Association
Article 15 As registered in accordance with law, the scope of business of the Company includes: General items: research and development of bio-chemical product technology; technical services, technology development, technology consultation, technology exchange, technology transfer, technology promotion; sales of software; operation and maintenance services of information system; production of Class I medical devices; sales of Class II medical devices; sales of Class I medical devices; office equipment leasing services; import and export of technology; import and export of goods; sales of chemical products (excluding licensed chemical products); production of chemical products (excluding licensed chemical products); manufacturing of specialty chemical products (excluding hazardous chemicals); sales of specialty chemical products (excluding hazardous chemicals). (Except for items subject to approval in accordance with laws and regulations, such business activities shall be carried out with business licenses independently in accordance with laws and regulations) Licensed items: operation of Class III medical devices; production of Class II medical devices; production of Class III medical devices. (For items subject to approval in accordance with laws and regulations, business activities can only be carried out after obtaining the approval of relevant departments, and the specific business items shall be subject to results of approval).	Article 15 As registered in accordance with law, the scope of business of the Company includes: General items: research and development of bio-chemical product technology; technical services, technology development, technology consultation, technology exchange, technology transfer, technology promotion; <u>software development; retail of computer software, hardware and auxiliary equipment; wholesale of computer software, hardware and auxiliary equipment; sales of electronic products; sales of communication equipment; sales of instruments and meters; computer system services; information systems integration services;</u> operation and maintenance services of information system; production of Class I medical devices; sales of Class II medical devices; sales of Class I medical devices; office equipment leasing services; import and export of technology; import and export of goods; sales of chemical products (excluding licensed chemical products); production of chemical products (excluding licensed chemical products); manufacturing of specialty chemical products (excluding hazardous chemicals); sales of specialty chemical products (excluding hazardous chemicals); <u>big data services; data processing and storage support services; internet data services; development of basic artificial intelligence software; development of artificial intelligence application software; sales of artificial intelligence hardware; artificial intelligence industry application systems integration services.</u> (Except for items subject to approval in accordance with laws and regulations, such business activities shall be carried out with business licenses independently in accordance with laws and regulations). Licensed items: operation of Class III medical devices; production of Class II medical devices; production of Class III medical devices; <u>Class II value-added telecommunications services; internet information services.</u> (For items subject to approval in accordance with laws and regulations, business activities can only be carried out after obtaining the approval of relevant departments, and the specific business items shall be subject to ~~results of approval~~ <u>the approval documents or licences issued by the relevant departments</u>).

The proposed amendments to the Articles of Association are subject to the approval by the Shareholders by passing a special resolution at the EGM. The proposed amendments to the Articles of Association will become effective upon the approval by the Shareholders at the EGM. Prior to that, the current Articles of Association shall remain effective.

The Articles of Association and its amendments were prepared in Chinese, without formal English version. As such, the English translation shall be for reference only. In case of any discrepancies, the Chinese version shall prevail.

EGM

The Board proposes to have the EGM to be held on Thursday, July 23, 2026, to consider and approve the resolution in relation to the Proposed Adjustment of Business Scope and the proposed amendments to the Articles of Association by way of a special resolution.

A circular containing, among other things, further details of the Proposed Adjustment of Business Scope and the proposed amendments to the Articles of Association, together with the notice of the EGM, will be published on the websites of the Company (www.diagens.com) and the Stock Exchange (www.hkexnews.hk) and despatched to the Shareholders on or before July 8, 2026.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
*Chairman of the Board, Executive Director and
General Manager*

Hangzhou, PRC, July 7, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.